Global Benzoic Acid Retagliptin Tablets Market Strategic Research Report

Scope of the Report

The global Benzoic Acid Retagliptin Tablets market size is predicted to grow from US$ 58.40 million in 2025 to US$ 31.57 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Fultagliptin Benzoate Tablets are innovative domestic oral hypoglycemic drugs belonging to dipeptidyl peptidase 4 (DPP-4) inhibitors. It selectively inhibits the activity of dipeptidyl peptidase 4, prolongs the action time of incretins in the body, stably regulates the secretion of insulin and glucagon, and thereby effectively controls blood glucose. With mild hypoglycemic effect and good tolerance, it is mainly applied to improve blood glucose and carry out chronic disease management in adult patients with type 2 diabetes, and occupies an important position in clinical hypoglycemic treatment.In 2025, global Fultagliptin Benzoate Tablets production reached approximately 2.1 million bottles.

As a domestic Class 1 innovative DPP-4 inhibitor, Fultagliptin Benzoate Tablets boast differentiated clinical advantages and policy support, enjoying broad development prospects in the type 2 diabetes treatment market. Independently developed by Salubris Pharmaceuticals, the drug was approved for marketing in 2024 and quickly included in the National Medical Insurance Catalogue, which greatly improves patients’ medication accessibility and market access capability. In clinical practice, it features a low risk of hypoglycemia, neutral impact on body weight and favorable tolerance. It can be used as monotherapy or combined with drugs such as Metformin to meet the treatment needs of patients at different disease stages. At present, the domestic DPP-4 inhibitor market is still dominated by imported original research drugs, while the supply of domestic innovative varieties is relatively insufficient. As one of the few domestic original research products, Fultagliptin Benzoate Tablets is expected to gradually replace imported products by virtue of price advantages and channel expansion. Meanwhile, with the rising prevalence of diabetes, the continuous improvement of the chronic disease management system and the growing demand in primary medical markets, this product has long-term sales growth potential. Driven by medical insurance policies, clinical guideline recommendations and corporate academic promotion, Fultagliptin Benzoate Tablets will hopefully become a key growth driver in the domestic hypoglycemic drug market and promote the breakthrough and development of domestic innovative drugs in the field of metabolic diseases.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Benzoic Acid Retagliptin Tablets market?

What factors are driving Benzoic Acid Retagliptin Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Benzoic Acid Retagliptin Tablets market opportunities vary by end market size?

How does Benzoic Acid Retagliptin Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Benzoic Acid Retagliptin Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 6 mg
• 12 mg

Segment by Combination Therapy

• Combined With Metformin
• Combined With Sulfonylureas

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Application

• Type 2 Diabetes Mellitus
• Auxiliary Blood Glucose Regulation
• Chronic Metabolic Disease Management
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Benzoic Acid Retagliptin Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Type 2 Diabetes Mellitus, Auxiliary Blood Glucose Regulation, Chronic Metabolic Disease Management evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact